InsidersTradesSigma
Follow the 华海药业 share price and the full insider trade history of the company, a publicly traded company based in China. Shares trade on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 华海药业 has published 3 insider filings. Market capitalisation: €24.4bn. The latest transaction was disclosed on 27 November 2023 (Purchase). Among the most active insiders: 陈保华. Every trade is accessible without an account.
3
Insider Decl.
n/a
Thresholds
€3m
3 ops.
Buy Volume
n/a
n/a
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,691 of 29,063 companies
37.5
score / 100
Value31
Quality44
FCF yld-3.0%
Earn yld1.1%
EV/EBITDA19.2x
ROE3.3%
Gross mgn60%
Net mgn3.1%
Debt/EBITDA4.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 November 2023
Acerca de 华海药业
华海药业 es una empresa del sector de la salud y farmacéutico, cotizada en la Bolsa de Shanghái. Se centra en la investigación, desarrollo y producción de medicamentos genéricos y productos farmacéuticos innovadores.